SAB Biotherapeutics, Inc. (SABS): Cash & Equivalents
$10.50M
As of 2025-12-31
$8.27M
As of 2026-06-30
-11.3%
3-year compound annual growth
-3.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.50M | +18.0% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $8.90M | -84.3% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $56.57M | +275.9% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $15.05M | n/a | 2024-03-29, Balance as of period end |
| 2022-06-30 | $16.62M | n/a | 2023-04-14, Balance as of period end |
| 2022-03-31 | $22.41M | n/a | 2023-04-14, Balance as of period end |
| 2021-12-31 | $33.21M | +163.3% | 2023-04-28, Balance as of period end |
| 2020-12-31 | $12.61M | n/a | 2023-04-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $10.50M | +18.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $12.36M | -24.1% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $59.52M | +87.8% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $82.98M | -49.4% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $178.80M | +83.4% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $182.53M | +28.4% |
Compare SABS, STRO, CRBU, AURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗